ArticleScientific reports2018
Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.Clinical rheumatology · 2025Pooled it
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Article
- Comparison of Efficacy and Safety of Different Medication Protocols in Patients with Immunoglobulin G4-Related Disease Based on Follow-up Time: A Systematic Review and Network Meta-analysis.Archives of rheumatology · 2026Article
- Features of IgG4-related sclerosing mesenteritis: A Chinese cohort study and literature review.Rheumatology and immunology research · 2025Article
- IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets.Allergy · 2025Review
- A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease.Rheumatology (Oxford, England) · 2025Article
- Comparison of clinical features between patients with and without renal involvement in IgG4-related disease.Clinical and experimental medicine · 2025Article
- IgG4-related Disease: Recent Topics on Immunological Aspects of This Disorder and Their Application in New Treatment Strategies.Internal medicine (Tokyo, Japan) · 2025Review
- IgG4-related retroperitoneal fibrosis presenting as a peripancreatic mass: a case series.Annals of medicine and surgery (2012) · 2025Article
- An Unusual Case of Chylous Ascites.Cureus · 2024Article
- HLA-DRB1 Is Associated with Therapeutic Responsiveness in IgG4-related Disease.Internal medicine (Tokyo, Japan) · 2024Article
- Immunoglobulin G4-Related Disease-Associated Dermatitis with Pruritus: A Positive Response to Dupilumab.Life (Basel, Switzerland) · 2023Article
- Performance of classification and diagnostic criteria for IgG4-related disease and comparison of patients with and without IgG4-related disease.Scientific reports · 2023Article
- IgG4-Related Disease Mimicking Unilateral Urothelial Carcinoma: A Rare Case Report and Literature Review.Clinical medicine insights. Case reports · 2023Article
- Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease.PloS one · 2023Article
- Human epididymis protein 4 (HE4) is a novel biomarker for fibrosis in IgG4-related disease and can predict poor prognosis.RMD open · 2022Article
- Risk factors for the recurrence of relapsing polychondritis.Arthritis research & therapy · 2022Article
- Retrospective analysis of IgG4-related disease cases at a tertiary care centre in India.Reumatologia · 2022Article
- Clinical Characteristics of Patients With IgG4-Related Disease Complicated by Hypocomplementemia.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4-0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4-0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4-0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.